GlaxoSmithKline ($GSK) and Daiichi Sankyo ($D4S.BE) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan. The Wall Street Journal points out that Japan's market has good growth potential because it currently uses many older vaccines and because the population is only beginning to vaccinate against some conditions that traditionally have been treated symptomatically. The deal is expected to be completed in the third quarter. Release | Story